Huang, Rui
Shang, Jia
Chen, Hong
Li, Jun
Xie, Qing
Feng, Jiajun
Wei, Lai
Rao, Huiying
Funding for this research was provided by:
Peking University People's Hospital Scientific Research Development Funds (RDJ2022-21)
Peking University Hepatology Institute Qi-Min Project (NA)
Bristol-Myers Squibb (AI452-018ST)
Article History
Received: 14 May 2023
Accepted: 19 December 2023
First Online: 10 January 2024
Declarations
:
: The study protocols were approved by a central review board (the ethics committee of Peking University People’ s Hospital), the institutional review boards of each participating center, and the China National Human Genetic Resource Management Office (2010). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s).
: Not applicable.
: LW has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and consulting for Gilead, Huahui, MSD, Pfizer, speaker for Ascletis Pharma, Bristol- Myers Squibb, Gilead, and Kaiyin. HR has received a speaker honorarium from Bristol-MyersSquibb, Gilead, and AbbVie. Other authors declare that they have no competing interests.